Skip to main content

Table 2 Serostatus of HBsAg, HCV, HSV-1 and CMV and Co-infection by KSHV and HSV-2 in study participants

From: Prevalence and correlates of Kaposi’s sarcoma-associated herpesvirus and herpes simplex virus type 2 infections among adults: evidence from the NHANES III data

Characteristic

KSHV

HSV-2

Infection, n/N (%)

aORs$

(95% CI)

P

Infection, n/N (%)

aORs$

(95% CI)

P

All subjects

2.05

  

31.03

  

HBV

 No

3.69

1.00

0.137

56.06

1.00

0.618

 Yes

7.94

2.45

(0.65,7.27)

 

51.85

1.18

(0.62,2.28)

 

HCV

 No

2.04

1.00

0.612

30.48

1.00

 < 0.001*

 Yes

2.21

1.22

(0.51,2.45)

 

50.37

2.16

(1.63,2.85)

 

HSV-1

 No

1.20

1.00

0.194

27.17

1.00

0.159

 Yes

1.99

1.37

(0.87,2.26)

 

32.13

0.92

(0.81,1.03)

 

HSV-2

 No

1.54

1.00

0.014*

–

–

–

 Yes

2.41

1.58

(1.09,2.27)

 

–

–

–

KSHV

 No

–

–

–

30.65

1.00

0.006*

 Yes

–

–

–

41.36

1.66

(1.15,2.37)

 

CMV

 No

0.88

1.00

0.001*

17.43

1.00

 < 0.001*

 Yes

2.40

2.12

(1.37,3.43)

 

35.55

1.59

(1.40,1.81)

 
  1. KSHV Kaposi’s sarcoma-associated herpesvirus, the KSHV seroprevalence was used antibodies to K8.1; HSV-2 Herpes simplex virus type 2; HBV Hepatitis B virus; HCV Hepatitis C virus; HSV-1 Herpes simplex virus type 1; CMV Cytomegalovirus; aORs adjusted odds ratios; CI confidence interval
  2. $OR and 95%CI adjusted for age, sex, race/ethnicity, education level and economic status as shown in Table 1
  3. Seroprevalence of HBsAg, HCV, HSV-1, HSV-2, KSHV and CMV, respectively
  4. *Statistically significant association
Back to article page

Virology Journal

ISSN: 1743-422X